October 22nd 2024
Nivolumab plus AVD outperformed brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma.
September 6th 2024
FDA Approves First Biosimilar for Non-Hodgkin Lymphoma
November 29th 2018The FDA has approved the first rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy.
FDA Approves Brentuximab Vedotin for Frontline CD30+ Peripheral T-Cell Lymphoma
November 16th 2018The Food and Drug Administration (FDA) has approved the use of brentuximab vedotin (Adcetris) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).
FDA Grants Breakthrough Designation to Brentuximab Vedotin for CD30+ PTCL
November 16th 2018The Food and Drug Administration (FDA) has granted a breakthrough therapy designation to brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the first-line treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Trial Induces 'Best Ever' Survival Data Among Young Patients with Certain T-Cell Cancers
July 10th 2018Adding nelarabine to escalating-dose methotrexate increased the 4-year disease-free survival rate to 91% in pediatric and young adult patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, according to results from the phase III AALL0434 trial.
Telephone Intervention Reduces Unplanned Hospitalizations for Patients With Blood Cancers
April 30th 2015A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.